Walleye Capital’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Walleye Capital’s Portfolio KRSA Stock Details KRSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-181	Closed	-$44K	–	2350
2021 Q4	$44K	Buy	+181	New	+$8.55K	﹤0.01%	1790
2021 Q2	–	Sell	-107	Closed	-$42K	–	1372
2021 Q1	$42K	Buy	+107	New	+$8.04K	﹤0.01%	1072

Other funds holding KRSA

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Walleye Capital's KRSA Position: Q1 2022 in Review

Walleye Capital sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q1 2022, closing a stake of 181 shares — an estimated $44K sold.

Walleye Capital first reported a position in KRSA in Q1 2021 and held it in 2 quarters. The position peaked at $44K in Q4 2021. 46 funds tracked by Wall St. Rank hold KRSA as of Q1 2022.

Walleye Capital reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Walleye Capital sold 181 Korsana Biosciences, Inc. Common Stock shares in Q1 2022, an estimated $44K.
Walleye Capital first reported a position in Korsana Biosciences, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
Walleye Capital's Korsana Biosciences, Inc. Common Stock position peaked at $44K in Q4 2021.
46 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q1 2022.

Based on Walleye Capital's 13F filing for Q1 2022, filed 16 May 2022.